Skip to main content
. 2007 Feb 28;13(8):1195–1203. doi: 10.3748/wjg.v13.i8.1195

Table 5.

Number of amino acids mutations observed in six different regions from NS5A protein, at baseline mean ± SD

NS5A region (aa range) 2 groups (D0) (n = 147) SVR (D0) (n = 99) NR (D0) (n = 48) SVR (M3) (n = 51) NR (M3) (n = 32) NR (M6) (n = 26)
ISDR (2209-2248) 1.5 ± 1.6 1.3 ± 1.7 1.9 ± 1.1 0.8 ± 0.8 2.1 ± 1.0 1.8 ± 1.2
PKRbd (2209-2274) 5.4 ± 2.1 5.3 ± 2.4 5.7 ± 1.2 4.7 ± 1.6 6.1 ± 1.0 5.7 ± 1.3
V3 (2353-2379) 5.5 ± 1.4 6.0 ± 1.5 4.7 ± 0.6 6.1 ± 1.3 4.8 ± 0.7 5.1 ± 0.6
Complete NS5A (1973-2208) 32.6 ± 5.6 33.9 ± 6.0 29.8 ± 3.7 31.7 ± 5.3 30.8 ± 3.9 31.9 ± 2.9
N-terminal part of NS5A (1973-2208) 12.4 ± 3.1 12.9 ± 3.3 11.6 ± 2.4 11.7 ± 2.0 11.2 ± 2.1 12.8 ± 2.1
C-terminal part of NS5A (2209-2419) 20.1 ± 3.9 21.1 ± 4.1 18.2 ± 2.4 20.1 ± 4.2 19.6 ± 2.9 19.4 ± 3.4

n: number of PCR products analyzed; SVR: Sustained Responders; NR: Non-Responders to IFN-ribavirin therapy; D0: beginning of the treatment; M3: 3 mo of treatment; M6: 6 mo of treatment.

HHS Vulnerability Disclosure